Inhibitor of Apoptosis Protein-Like Protein-2 as a Novel Serological Biomarker for Breast Cancer

International Journal of Molecular Sciences

Mingjun Xiang³  Wei Zhou⁴  Dandan Gao²  Xiansong Fang¹ 

[1] Clinical Laboratory, the First Affiliated Hospital, Gannan Medical University, Ganzhou 341000, China; E-Mail:;Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming 650118, China; E-Mail:;Department of Biochemistry & Molecular Biology, College of Medical Science, Jishou University, Jishou 416000, China;Hunan Provincial Key Laboratory for Biology and Control of Plant Diseases and Insect Pests, College of Bio-Safety Science & Technology, Hunan Agricultural University, Changsha 410128, China; E-Mail:

关键词: ILP-2;    breast cancer;    serological biomarker;   

DOI  :  10.3390/ijms131216737

来源: mdpi

【 摘 要 】

Inhibitor of apoptosis protein-like protein-2 (ILP-2) has only been detected in the testis and in lymphoblastoid cells. Although previous studies have not reported the presence of ILP-2 in breast cancer tissues, this study indicates the presence of ILP-2 in breast cancer serum samples. To validate whether ILP-2 is a novel serological biomarker for breast cancer, we conducted two-dimensional gel electrophoresis (2DE) and matrix-assisted laser desorption/ionization-time of flight mass spectrometry analysis on 400 breast cancer serum samples and 40 non-cancer serum samples (i.e., healthy controls). We then performed a Western blot analysis of 10 breast cancer serum samples and 10 non-cancer serum samples. Finally, we analyzed 35 serum samples from healthy controls or subjects with breast cancer, other types of cancer, galactophore hyperplasia or breast cancer post-surgery by using 2DE and enzyme-linked immunosorbent assay. Our results indicate that ILP-2 is a novel breast cancer biomarker in the peripheral blood.

【 授权许可】

CC BY   
© 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.